Skip to main content
SpringerLink
Log in

Pharmacological Treatment of Obsessive Compulsive Disorder

  • Chapter
New Directions in Affective Disorders

Abstract

The most widely used drug for the treatment of obsessive compulsive disorder (OCD) is clomipramine. It may therefore be helpful to review the evidence for efficacy for clomipramine alone and in relation to other antidepressants to be found in double-blind controlled studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Thoren P, Asberg M, Cronholm B, et al. Clomipramine treatment of obsessive compulsive disorder. Arch Gen Psychiatry 1980; 37: 1281–1285.

    PubMed  CAS  Google Scholar 

  2. Insel TR, Murphy DL, Cohen RM, et al. Clomipramine and clorgyline in OCD. Arch Gen Psychiatry 1983; 40: 605–612.

    PubMed  CAS  Google Scholar 

  3. Marks IM, Stern RS, Mawson D, et al. Clomipramine and exposure for obsessive compulsive rituals. Br J Psychiatry 1980; 136: 1–25.

    Article  PubMed  CAS  Google Scholar 

  4. Marks IM, Lelliott P, Basoglu M, et al. Clomipramine, self-exposure and therapist-aided exposure. Br J Psychiatry 1988; 152: 522–535.

    Article  PubMed  CAS  Google Scholar 

  5. Flament MF, Rapoport JL, Berg CJ, et al. Clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry 1985; 42: 977–983.

    PubMed  CAS  Google Scholar 

  6. Montgomery SA. Clomipramine in obsessional neurosis: a placebo controlled trial. Pharm Med 1980; 1: 189–192.

    Google Scholar 

  7. DeVeaugh-Geiss J, Katz R, Landau P. A multi-centre trial of Anafranil in obsessive compulsive disorder. Psychopharm 1988; 96 Suppl.: 80.

    Google Scholar 

  8. Ananth J, Pecknold JC, Van den Steen N, et al. Double blind study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol 1981; 5: 257–262.

    Article  PubMed  CAS  Google Scholar 

  9. Zohar J, Insel TR. Drug treatment of obsessive-compulsive disorder. J Affect Disorders 1987; 13: 193–202.

    Article  PubMed  CAS  Google Scholar 

  10. Leonard H, Swedo S, Rapoport JL, Coffey M, Cheslow D. Treatment of childhood obsessive compulsive disorder with clomipramine and desmethylimipramine: a double-blind crossover comparison. Psychopharmacology Bulletin. 1987; 2493–95.

    Google Scholar 

  11. Volavka J, Neziroglu F, Yaryura-Tobias JA. Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatr Res 1985; 14: 83–91.

    Article  Google Scholar 

  12. Foa EB, Steketee G, Kozak MJ, et al. Effects of imipramine on depression and on obsessive-compulsive symptoms. In: Abstracts, Annual Meeting, American College of Neuropsychopharmacology, 1985; 38.

    Google Scholar 

Download references

Authors
  1. Stuart A. Montgomery
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naomi Fineberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deirdre Montgomery
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Jerusalem Mental Health Center-Ezrath Nashim, 91001, Jerusalem, Israel

    Bernard Lerer M.D. (Director of Research, Associate Professor) (Director of Research, Associate Professor)

  2. Department of Psychiatry, Hebrew University, 91001, Jerusalem, Israel

    Bernard Lerer M.D. (Director of Research, Associate Professor) (Director of Research, Associate Professor)

  3. University of Pittsburgh, 15213, Pittsburgh, PA, USA

    Samuel Gershon M.D. (Vice President for Research in the Medical and Health Care Division; Associate Vice President for Research in the Health Sciences, Professor of Psychiatry, Associate Research Director for Neurosciences) (Vice President for Research in the Medical and Health Care Division; Associate Vice President for Research in the Health Sciences, Professor of Psychiatry, Associate Research Director for Neurosciences)

  4. Department of Psychiatry, University of Pittsburgh School of Medicine, 15213, Pittsburgh, PA, USA

    Samuel Gershon M.D. (Vice President for Research in the Medical and Health Care Division; Associate Vice President for Research in the Health Sciences, Professor of Psychiatry, Associate Research Director for Neurosciences) (Vice President for Research in the Medical and Health Care Division; Associate Vice President for Research in the Health Sciences, Professor of Psychiatry, Associate Research Director for Neurosciences)

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag New York Inc.

About this chapter

Cite this chapter

Montgomery, S.A., Fineberg, N., Montgomery, D. (1989). Pharmacological Treatment of Obsessive Compulsive Disorder. In: Lerer, B., Gershon, S. (eds) New Directions in Affective Disorders. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-3524-8_93

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-3524-8_93

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-96769-1

  • Online ISBN: 978-1-4612-3524-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation